MISSISSAUGA, ON, Feb. 26, 2021 /CNW/ - Covalon Technologies Ltd.
(the "Company" or "Covalon") (TSXV: COV) (OTCQX: CVALF), an
advanced medical technologies company, will release its fiscal 2021
first quarter financial results on Monday
March 1st 2021 before markets open. A conference
call to discuss the financial results will be held on Monday March 1st 2021 at 9:00am EST. To participate in the conference
call, please dial:
Local (Toronto):
416.764.8659
North American Toll Free: 1.888.664.6392
Confirmation Number: 13753009
A recording of the call will be available by calling
416.764.8677 or 1.888.390.0541 and entering the encore replay entry
code 753009# from March
1st 2021 at 12:00pm
EST to March 15th
2021 at 11:59pm EST. A recording of
the call will be available on www.covalon.com on the Events page
under News & Events on the Investors tab.
Copies of Covalon's financial statements and MD&A can be
obtained on SEDAR at www.sedar.com and on the Investors tab of the
Company's website at www.covalon.com.
About Covalon
Covalon Technologies Ltd. is a
researcher, developer, manufacturer, and marketer of
patent-protected medical products that improve patient outcomes and
save lives in the areas of advanced wound care, infection
management and surgical procedures. Covalon leverages its patented
medical technology platforms and expertise in two ways: (i) by
developing products that are sold under Covalon's name; and (ii) by
developing and commercializing medical products for other medical
companies under development and license contracts. The
Company is listed on the TSX Venture Exchange, having the symbol
COV and trades on the OTQX Market under the symbol CVALF. To learn
more about Covalon, visit our website at www.covalon.com.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
This news release contains forward-looking statements which
reflect the Company's current expectations regarding future events.
The forward-looking statements are often, but not always,
identified by the use of words such as "seek", "anticipate", "plan,
"estimate", "expect", "intend" and statements that an event or
result "may", "will", "should", "could" or "might" occur or be
achieved and other similar expressions. These forward-looking
statements involve risk and uncertainties, including completion of
integration of the AquaGuard acquisition, the difficulty in
predicting product approvals, acceptance of and demands for new
products, the impact of the products and pricing strategies of
competitors, delays in developing and launching new products, the
regulatory environment, fluctuations in operating results, the
impact and timing of COVID-19 on operating activities and market
conditions, and other risks, any of which could cause
results, performance, or achievements to differ materially from the
results discussed or implied in the forward-looking statements.
Many risks are inherent in the industry; others are more specific
to the Company. Investors should consult the Company's ongoing
quarterly filings for additional information on risks and
uncertainties relating to these forward-looking statements.
Investors should not place undue reliance on any forward-looking
statements. The Company assumes no obligation to update or alter
any forward-looking statements whether as a result of new
information, further events or otherwise.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/covalon-announces-conference-call-to-discuss-first-quarter-financial-results-301236702.html
SOURCE Covalon Technologies Ltd.